Streetwise Management Q&As


CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby
Source: George S. Mack of The Life Sciences Report  (2/11/16)
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (CRMD:NYSE.MKT) is developing a platform that has shown impressive results in preventing serious bloodstream infections. In this interview with The Life Sciences Report, CorMedix CEO Randy Milby addresses his company's science, pipeline and market opportunity. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting. More >


Stewart Washer

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics
Source: Peter Byrne of The Life Sciences Report  (2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. More >


Leo Ehrlich

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades. More >


James Brown

Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Sometimes wonderful ideas live on and create value for the ages. Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp., which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech. More >


Trent D'Ambrosio

Inception Mining's Diverse Batch of Assets Offers Production Now, Growth Later
Source: Brian Sylvester of The Gold Report  (1/26/16)
Inception Mining is producing gold at its Clavo Rico operation in Honduras and is preparing to begin contract gold mining at its U.P. & Burlington project in the mountains of Idaho. Add in resource expansion and some exploration upside in Nevada and you have a story with lots of interesting angles. Inception CFO and Director Trent D'Ambrosio shares with The Gold Report his company's plans to boost production and expand mine life at Clavo Rico. More >


Morgan Poliquin

Almaden: Succeeding in a Tough Resource Market with World-Class Management and Gold-Silver Discovery
Source: JT Long of The Gold Report  (1/13/16)
With approximately $5.5 million in the bank, a 3.5-million-ounce gold equivalent Measured and Indicated resource, zero debt and a robust, updated preliminary economic assessment, Almaden Minerals Ltd. CEO Morgan Poliquin says the company is in position to not only survive this tough market but to continue adding significant value at a deep discount. While other companies are trying to figure out how to keep the lights on, Almaden has been active. The company recently completed a spinout of a large portfolio of exploration projects and royalties—including a royalty on Ixtaca—into Almadex Minerals Inc. and purchased an option on a mint condition mill that reduced the initial capital cost estimate by some $70 million. In this interview with The Gold Report, the second-generation geologist points to the fact that 95% of the Tuligtic property, which hosts the Ixtaca Zone, remains unexplored and that the company can drill for about a third of what most operators pay. He says that the company’s market cap is less than the savings from the purchase of the mill, as an indication that a potential buyout is a plausible scenario. More >


Jon Awde

Gold Standard Ventures Is Uncovering Bonanza Grades in Nevada's Carlin Trend
Source: JT Long of The Gold Report  (1/4/16)
In the wake of what has been described as "obscene" intersects at Gold Standard Ventures' newly consolidated Railroad-Pinion project and a corresponding jump in the share price, CEO Jon Awde shares with The Gold Report readers his plans for moving the project forward in 2016. More >


James Joyce

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report  (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE. More >


Redstar Gold's Ken Booth Discovers Formula for Success in the Alaskan Gold Fields
Source: Peter Byrne of The Gold Report  (12/17/15)
Redstar Gold Corp. has locked down a district-scale, high-grade gold property off the coast of Alaska. In an interview with The Gold Report, Redstar CEO Ken Booth reveals the secrets of the Unga Project: high-grade gold in the ground, everywhere. Redstar has a focused plan to keep drilling the mineralized property; Booth is looking to add weight to the company's sparkling roster of stockholders and institutional partners. More >


Andrew Gengos

An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos
Source: George S. Mack of The Life Sciences Report  (12/16/15)
Los Angeles-based ImmunoCellular Therapeutics Ltd. is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive. In this interview with The Life Sciences Report, Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial. More >


Cary Vance

Robotics Are Key to New Millennium Surgeries: Hansen Medical's Cary Vance
Source: Gail Dutton of The Life Sciences Report  (11/13/15)
Interventional radiology has been described as the surgery of the new millennium by Stanford Healthcare, offering less invasive procedures, more precise placement of catheters and, often, fewer complications for patients and higher throughput for healthcare facilities. Robotics is making this new area of medicine possible. Cary G. Vance, CEO of Hansen Medical Inc., tells The Life Sciences Report about disruptive advances in interventional radiology and Hansen's own revolutionary robotic catheters. More >


Rudi Fronk

With KSM Permits in Hand, Seabridge Is Now Set to Leverage the Coming Bull Market in Gold
Source: Kevin Michael Grace of The Gold Report  (11/5/15)
With Proven and Probable reserves of 38 million ounces of gold and 10 billion pounds of copper, the potential of Seabridge Gold's KSM project in British Columbia has long been sky-high. In this interview with The Gold Report, Chairman/CEO Rudi Fronk explains that his company has always maximized its leverage to the price of gold. So now, with KSM fully permitted and greatly enhanced by the discovery of higher-grade gold and copper, and a bull market in gold now on the way, the recent strong gains made by investors in his company are likely only the beginning. More >


Shawn Patrick O'Brien

How Cipher Pharmaceuticals Is Developing Products for Dermatological Disorders
Source: Dan Levy for The Life Sciences Report  (11/4/15)
Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for specific dermatological indications, but few have been able to build product portfolios with the range of therapeutic and consumer products currently marketed by Cipher Pharmaceuticals. In this interview with The Life Sciences Report, Shawn Patrick O'Brien, president and CEO of Cipher, describes his company's ongoing efforts to address unmet needs in dermatology. More >


Mark Brennan

Sierra Metals Sees Organic Growth Leading to a Billion-Dollar Valuation
Source: Kevin Michael Grace of The Gold Report   (11/2/15)
Since 2010, Sierra Metals has managed to continually increase production at its Bolivar and Cusi mines in Mexico and its Yauricocha mine in Peru while increasing reserves. Even better, all three mines are part of huge land packages barely explored. In this interview with The Gold Report, Sierra Metals President and CEO Mark Brennan explains how he has centralized and rationalized company operations, how he is modernizing production and how he intends to grow Sierra internally to become a large-cap producer with a billion-dollar-plus market cap. More >


James Joyce

Aethlon Medical's Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce
Source: Gail Dutton of The Life Sciences Report  (10/28/15)
Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James "Jim" Joyce tells The Life Sciences Report how this device is helping transform modern healthcare. More >


Rik Deitsch

OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch
Source: Gail Dutton of The Life Sciences Report  (10/21/15)
A strategy of over-the-counter sales helps derisk Nutra Pharma Corp. as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates how he plans to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases. More >


Sam  Riggall

Cleaner Water and Stronger Aluminum Drive Clean TeQ's Future
Source: Kevin Michael Grace of The Gold Report  (10/21/15)
Australia's Clean TeQ Holdings Limited, a long-time industry leader in environmental remediation, has recently partnered with China's largest power generator to treat waste water with its unique continuous-ion technology. This technology also allows Clean TeQ to extract metals from minerals and industrial waste, but as Clean TeQ Chairman Sam Riggall explains in this interview with The Gold Report, the company is also on track to open the world's first standalone scandium mine, and has already inked collaboration agreements with the end users that will use this currently rare metal to make aluminum lighter and stronger. More >


Ross Macdonald

Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald
Source: Gail Dutton of The Life Sciences Report  (10/14/15)
Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide. More >


Joseph Wagner Charles Wiseman Saeid Babaei

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >


Michael Hopley

Sunridge Is Now Good to Go at Its Asmara VMS Project in Eritrea
Source: Kevin Michael Grace of The Gold Report  (9/24/15)
It's been a very active decade filled with milestones for Sunridge Gold, and now following the September signing of a comprehensive permitting agreement with its partner, the government of Eritrea, the Canadian junior is set to begin production in 2016. In this interview with The Gold Report, President and CEO Michael Hopley discusses the riches of his company's copper, gold, zinc and silver deposits and looks forward to becoming as successful as Nevsun has been. More >


Robert Erwin

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >


Travis McPherson Leigh Curyer

NexGen Energy: A Bold New Uranium Venture for a World in Short Supply
Source: Peter Byrne of The Energy Report  (9/8/15)
NexGen Energy Ltd. has a strong, well-focused uranium project located in the cornucopia of the Athabasca Basin. Without hype, CEO Leigh Curyer and Corporate Development Manager Travis McPherson, part of an experienced team of "pure-play uranium professionals," make the case for investment in a project with obvious legs. More >


Max Porterfield

Resource Capital Funds Backs Callinex's Strategy near HudBay Operations
Source: Kevin Michael Grace of The Gold Report  (9/3/15)
Manitoba's Flin Flon Greenstone Belt has yielded VMS discoveries resulting in dozens of mines. Callinex Mines has been a big part of that success for almost a century and believes it has the properties that will become the district's latest winners. In this interview with The Gold Report, Callinex President and CEO Max Porterfield explains how high-grade assays and proximity to existing producers could lead to his company discovering the ore that HudBay will soon need. More >


Donald McCaffrey

Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey
Source: Gail Dutton of The Life Sciences Report  (8/26/15)
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events (MACE)—death, heart attacks, strokes and heart failure, particularly in diabetic patients—in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster. More >


Steven Dischler

Quaterra Resources Has the Property, the People and the Partner for Large-Scale Nevada Copper Mining
Source: Kevin Michael Grace of The Gold Report  (8/20/15)
Few copper juniors hold the promise that Quaterra Resources does. Its 51 square miles in Nevada contains a past-producing mine. Its management is savvy and well seasoned. And it is backed by the strength of global player Freeport-McMoRan Nevada LLC, a wholly owned subsidiary of Freeport Minerals Corporation, which in turn is a wholly owned subsidiary of Freeport-McMoRan Inc. In this interview with The Gold Report, President and CEO Steven Dischler tells us why he believes his company's Bear project could open up a whole copper district. More >


Showing Results: 26 to 50 of 97 Prev Next